EGFR-TKI SENSITIZING MUTATION
Clinical trials for EGFR-TKI SENSITIZING MUTATION explained in plain language.
Never miss a new study
Get alerted when new EGFR-TKI SENSITIZING MUTATION trials appear
Sign up with your email to follow new studies for EGFR-TKI SENSITIZING MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a dose increase control lung cancer that Isn't shrinking?
Disease control Not yet recruitingThis study tests whether a higher dose (160 mg) of the drug firmonertinib can improve outcomes for people with advanced EGFR-mutant non-small cell lung cancer whose tumors have stayed stable but not shrunk after 8 weeks on the standard 80 mg dose. About 28 adults aged 18-75 with …
Matched conditions: EGFR-TKI SENSITIZING MUTATION
Phase: PHASE2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated May 22, 2026 13:54 UTC
-
New hope for lung cancer patients with brain lining spread: drug combo trial launches
Disease control Not yet recruitingThis study tests a combination of two treatments for people with a specific type of lung cancer (NSCLC with EGFR mutation) whose cancer has spread to the lining of the brain or spinal cord (leptomeningeal metastasis) after prior targeted therapy. The treatment combines an oral dr…
Matched conditions: EGFR-TKI SENSITIZING MUTATION
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated May 19, 2026 11:47 UTC